...
首页> 外文期刊>Retrovirology >Cellular fatty acid synthase is required for late stages of HIV-1 replication
【24h】

Cellular fatty acid synthase is required for late stages of HIV-1 replication

机译:HIV-1复制的晚期阶段需要细胞脂肪酸合酶

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Like all viruses, HIV-1 relies on host systems to replicate. The human purinome consists of approximately two thousand proteins that bind and use purines such as ATP, NADH, and NADPH. By virtue of their purine binding pockets, purinome proteins are highly druggable, and many existing drugs target purine-using enzymes. Leveraging a protein affinity media that uses the purine-binding pocket to capture the entire purinome, we sought to define purine-binding proteins regulated by HIV-1 infection. Using purinome capture media, we observed that HIV-1 infection increases intracellular levels of fatty acid synthase (FASN), a NADPH-using enzyme critical to the synthesis of de novo fatty acids. siRNA mediated knockdown of FASN reduced HIV-1 particle production by 80%, and treatment of tissue culture cells or primary PBMCs with Fasnall, a newly described selective FASN inhibitor, reduced HIV-1 virion production by 90% (EC50?=?213?nM). Despite the requirement of FASN for nascent virion production, FASN activity was not required for intracellular Gag protein production, indicating that FASN dependent de novo fatty acid biosynthesis contributes to a late step of HIV-1 replication. Here we show that HIV-1 replication both increases FASN levels and requires host FASN activity. We also report that Fasnall, a novel FASN inhibitor that demonstrates anti-tumor activity in vivo, is a potent and efficacious antiviral, blocking HIV-1 replication in both tissue culture and primary cell models of HIV-1 replication. In adults, most fatty acids are obtained exogenously from the diet, thus making FASN a plausible candidate for pharmacological intervention. In conclusion, we hypothesize that FASN is a novel host dependency factor and that inhibition of FASN activity has the potential to be exploited as an antiretroviral strategy.
机译:与所有病毒一样,HIV-1依赖于主机系统来复制。人纯素由大约两千千种蛋白质组成,可结合和使用嘌呤,如ATP,NADH和NADPH。凭借其嘌呤粘合口袋,纯素蛋白质是高度可借药,并且许多现有的药物靶向嘌呤使用酶。利用使用嘌呤结合口袋的蛋白质亲和培养基来捕获整个纯纯蛋白,我们寻求定义通过HIV-1感染调节的嘌呤结合蛋白。使用纯素捕获培养基,我们观察到HIV-1感染增加了细胞内水平的脂肪酸合酶(FASN),一种对Novo脂肪酸合成至关重要的NADPH-使用酶。 siRNA介导的Fasn敲低的敲低80%的颗粒产量降低了80%,并用FasnAll处理组织培养细胞或原发性PBMC,一种新描述的选择性FasN抑制剂,将HIV-1病毒虫产病毒患者降低90%(EC50?=?213? nm)。尽管需要FASN进行新生的恶毒群岛生产,但细胞内GAG蛋白质产生不需要FASN活性,表明FASN依赖性DE Novo脂肪酸生物合成有助于HIV-1复制的晚期步骤。在这里,我们显示HIV-1复制均增加FASN级别并需要主机FASN活动。我们还报告说,Fasnall是一种在体内显示抗肿瘤活性的新型FasN抑制剂是一种有效和有效的抗病毒,阻断HIV-1复制的组织培养和原代细胞模型中的HIV-1复制。在成人中,大多数脂肪酸都是从饮食中外源地获得的,从而使FASN成为药理干预的合理候选者。总之,我们假设FASN是一种新的宿主依赖因子,并且对FasN活性的抑制具有潜力作为抗逆转录病毒策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号